Carl Zeiss Meditec remains strong
(Thomson Reuters ONE) -
Carl Zeiss Meditec AG /
Carl Zeiss Meditec remains strong
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
Growth in all strategic business units and reporting regions. Further increase
in profitability.
JENA - 12 August 2011
Medical technology company Carl Zeiss Meditec successfully continued on its
growth course in the third quarter and achieved a significant increase in
revenue compared with the same period of the previous year.
"I am particular pleased that this substantial growth in revenue has also had a
positive effect on earnings," says Dr. Ludwin Monz, President and CEO of Carl
Zeiss Meditec AG. The EBIT margin increased from 12.2 percent in the same period
of the previous year to 13.6 percent. "This takes us another step closer to
achieving our objective of increasing our margin to 15 percent by around 2015,"
continues Dr. Monz.
Carl Zeiss Meditec has a broad business portfolio, ranging from ophthalmology,
through microsurgery, to new applications in radiotherapy. "All strategic
business units and reporting regions are contributing to our growth. This shows
that our company is in a stable position," says Dr. Ludwin Monz.
Key figures at a glance
In the first 9 months of the current financial year Carl Zeiss Meditec generated
consolidated revenue of 555.5 million euros (previous year: 490.8 million
euros). This represents an increase of 13.2 percent over the previous year.
Growth came from all strategic business units (SBUs). Both the overall positive
trend in the market during the reporting period and the further improvement in
the company's position as a result of innovative new products contributed to
this development. The Microsurgery SBU grew by 20.8 percent compared with the
previous year. The significantly higher sales of the innovative radiotherapy
device INTRABEAM contributed to this. While the Ophthalmic Systems SBU grew by
8.3 percent, the Surgical Ophthalmology SBU contributed to overall earnings with
growth of 7.7 percent.
Revenue growth comes from all reporting regions of Carl Zeiss Meditec. The
"Asia/Pacific" region achieved the greatest growth in revenue of 174.2 million
euros (23.9 percent). As in the previous quarters, China, India and Southeast
Asia showed the most significant growth. The Americas region also achieved
double-digit growth of 11.6 percent, to 188.5 million euros. This region
continues to be dominated by the USA, although development in Central and South
America is also encouraging. The EMEA region is the strongest market in terms of
revenue generation, growing by 6.3 percent through the sale of products and
solutions to a value of 192.8 million euros.
Earnings before interest and taxes (EBIT) increased to 75.7 million euros
(previous year: 60 million euros). The EBIT margin increased from 12.2 percent
to 13.6 percent.
"We shall remain on our present course," says Dr. Ludwin Monz. Our stable
strategic presence in businesses and regions makes me optimistic about the
longer-term development of our company. Particularly in light of the current
imponderables concerning the global economy, I consider Carl Zeiss Meditec to be
well equipped," said Dr. Monz.
Revenue by strategic business unit
Figures in 9 Months 2009/2010 9 Months 2010/2011 Change from
'000 euros previous year
Ophthalmic Systems 231,660 250,933 +8.3%
Surgical Ophthalmology 65,039 70,062 +7.7%
Microsurgery 194,132 234,503 +20.8%
Revenue by region
Figures in 9 Months 2009/2010 9 Months 2010/2011 Change from previous
'000 euros year
EMEA 181,296 192,769 +6.3%
Americas 168,964 188,523 +11.6%
Asia/Pacific region 140,571 174,206 +23.9%
Contact for the press
Petra Rettenmaier, Director Corporate Communications, Carl Zeiss Meditec AG,
Phone: +49 36 41 220-331, Email: press(at)meditec.zeiss.com
Patrick Kofler, Director Investor Relations, Carl Zeiss Meditec AG,
Phone: +49 36 41 220-106, Email: investors(at)meditec.zeiss.com
www.meditec.zeiss.com/press
--- End of Message ---
Carl Zeiss Meditec AG
Goeschwitzer Strasse 51-52 Jena Germany
WKN: 531370;ISIN: DE0005313704;Index:Prime All Share,TECH All Share,TecDAX;
Listed: Freiverkehr in Börse Stuttgart,
Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg,
Freiverkehr in Börse Berlin,
Freiverkehr in Börse Düsseldorf,
Freiverkehr in Bayerische Börse München,
Freiverkehr in Niedersächsische Börse zu Hannover,
Prime Standard in Frankfurter Wertpapierbörse,
Regulierter Markt in Frankfurter Wertpapierbörse;
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Carl Zeiss Meditec AG via Thomson Reuters ONE
[HUG#1538087]
Unternehmensinformation / Kurzprofil:
Datum: 12.08.2011 - 06:55 Uhr
Sprache: Deutsch
News-ID 57199
Anzahl Zeichen: 6074
contact information:
Town:
Jena
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 217 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Carl Zeiss Meditec remains strong"
steht unter der journalistisch-redaktionellen Verantwortung von
Carl Zeiss Meditec AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
